Medical Cannabis and Cardiovascular Disease

Medical Cannabis and Cardiovascular Disease

By Dr. François Halle, MFT Cannabinoid Therapy Specialist

As the number one killer in Canada, cardiovascular (heart) disease affects approximately 600,000 Canadians with almost 50,000 new cases diagnosed each year. A healthy lifestyle is essential to controlling this extremely serious illness which is often caused or exacerbated by smoking, poor diet and obesity. In addition, cannabidiol (CBD), the main non-psychoactive compound in cannabis has shown to drastically improve blood flow and reduce inflammation in heart disease sufferers. 

Medical Cannabis and Cardiovascular Disease

Rapid initiation of CBD treatment post MI (myocardial infarction, commonly known as a heart attack), has shown to reduces myocardial dysfunction, cardiac fibrosis, oxidative-nitrative stress, inflammation and cell death (Rajesh, et al., 2010). In addition, administering CBD shortly after a myocardial infarction can reduce infarct size and myocardial inflammation, thus showing potential as a treatment for myocardial ischemia (blockage in the heart’s arteries caused by reduced blood flow). The modulating effects on the immune system from CBD also decreases the risk of thrombus formation and plaque formation in the arterial system. (Durst, et al., 2007). The use of CBD capsules has also shown to cause a significant decrease in body weight gain and reduce triglycerides and free lipid levels in the bloodstream (Ignatowska-Jankowska, Jankowski & Swiergiel, 2011) and (Silvestri, et al., 2015).

If you or a loved one suffers from diabetes and are interested in accessing safe, effective medical cannabis, register with Marijuana for Trauma (MFT) by clicking here

For more information, please contact MFT at 1-855-MFT-0420 or email info@mftgroup.ca


Leave a Reply

Your email address will not be published. Required fields are marked *